All filters
Videos
Zika and other emerging viruses in the Americas | Mehul Suthar
Presented at:
HIV DART and Emerging Viruses 2018
Videos
Gertrude Elion Distinguished Lecturer Award Lecture: Innovation with an Impact: Development of HIV and TB drugs | Paul Stoffels, MD
Presented at:
HIV DART and Emerging Viruses 2018
Videos
HIV reservoir dynamics: Implications for HIV latency establishment and reversal | Deanna Kulpa, PhD
Presented at:
HIV DART and Emerging Viruses 2018
Videos
State of the Art Lecture: Molecular basis for HIV latency | Jonathan Karn, PhD
Presented at:
HIV DART and Emerging Viruses 2018
Videos
Understanding barriers to HIV cure | Robert Siliciano, MD, PhD
Presented at:
HIV DART and Emerging Viruses 2018
Videos
Baricitinib reverses HIV associated neurocognitive disorders and reservoir seeding in a SCID mouse model | Christina Gavegnano, PhD
Presented at:
HIV DART and Emerging Viruses 2018
Videos
State of the Art Lecture: Harnessing the immune system to eliminate and/or control HIV | Steven Deeks, MD
Presented at:
HIV DART and Emerging Viruses 2018
Videos
Barry-Wainberg DART Achievement Award Lecture: Overview of the research conducted at the Irsicaixa Foundation | Bonaventura Clotet, MD, PhD
Presented at:
HIV DART and Emerging Viruses 2018
Slidesets
Clinical Case presentation | Elena Orlova-Morozova, PhD
Presented at:
Russian HIV Clinical Forum 2018
Slidesets
Two Drug Regimens - Pros and Cons | Jürgen Rockstroh, MD
Presented at:
Russian HIV Clinical Forum 2018
Slidesets
Optimal use on integrase inhibitors in women and special populations (such as Injection drug users, HCV co-infected) | Elena Stepanova, MD
Presented at:
Russian HIV Clinical Forum 2018
Slidesets
Optimal use of integrase inhibitors in routine clinical practice | Anton Pozniak, MD, FRCP
Presented at:
Russian HIV Clinical Forum 2018
Meeting
Russian HIV Clinical Forum 2018
Slidesets
Abstract: A pharmacometric framework for dose individualisation of sunitinib in GIST (#O2) | Maddalena Centanni
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Rationale for selecting combinations with immunotherapy | Howard Gurney, MBBS, FRACP
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Immunotherapy of prostate cancer and urothelial cancer. Future directions | Winald Gerritsen, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS | Michelle Rudek, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Drug-Drug interactions with targeted oncolytics (in particular PPIs and TKIs) | Ron Mathijssen, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Drug-drug interaction management with DDI-Predictor | Michel Tod, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: Food intervention to make therapy with pazopanib more patient friendly and affordable (#06) | Floor Lubberman
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
The value of surrogate endpoints in the benefit-risk assessment of new drugs | Gabe Sonke, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: Novel online drug-drug interaction resource reveals clinically relevant interactions in >20% of the searches (#05) | Stefanie Krens
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: A Pharmacokinetic-Pharmacodynamic binding model of Bevacizumab to VEGF as a tool to optimize treatment (#07) | Apostolos Papachristos
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: A generalisable pharmacokinetic-pharmacodynamic (PKPD) model of savolitinib, a novel MET tyrosine kinase inhibitor, to explore extent and duration of target inhibition required for optimal efficacy across a range of tumour xenograft models (#O8)
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018